The effect of cessation of phenobarbital and dieldrin treatment on hepatic focal lesion growth in male B6C3F1 mice was investigated. Following induction of lesions by diethylnitrosamine, mice were placed on control NIH-07 diet (control diet) or NIH-07 diet containing either dieldrin (10.0 mg/kg diet) or phenobarbital (500 mg/kg diet). Mice were sacrificed after 30 and 60 days of dietary treatment Two additional groups of mice were fed either the dieldrinor phenobarbital-containing diet for 30 days followed by feeding of NIH-07-only diet for an additional 30 days. The effect of treatment and removal of dieldrin or phenobarbital on lesion growth was examined by measuring both the number of focal lesions per liver and the relative volume of focal lesions. In addition, the rate of cell proliferation and programmed cell death in focal lesion growth was investigated by examining DNA synthesis and apoptosis in the focal lesions. Dietary dieldrin or phenobarbital increased the number of focal lesions and the focal lesion volume. In both dieldrin-and phenobarbital-treated mice, an increased number of eosinophilic lesions were seen. The focal lesion volume was increased in both eosinophilic and basophilic lesions. Dieldrin and phenobarbital treatment also increased the DNA synthetic labeling index in both eosinophilic and basophilic lesions. Removal of dieldrin or phenobarbital from the diet after 30 days of promoter treatment decreased the total number and volume of hepatic focal lesions. The labeling index of the focal lesions was also decreased in these mice. At the terminal sacrifice, the percentage of apoptotic cells in focal lesions was higher in mice fed dieldrin-or phenobarbital-containing diets for the entire 60 days than in mice returned to control diet for the last 30 days. Eosinophilic lesions were more dependent on the presence of a promoting stimulus than the basophilic lesions. These data indicate that induction and maintenance of the growth of some preneoplastic lesions in the mouse may be dependent upon continuous tumor promoter treatment
Introduction
Hepatocarcinogenesis is a multi-stage process. It is characterized by a step-wise alteration of a normal cell to a preneoplastic intermediate that has the ultimate potential to
•Abbreviations: PB, phenobarbital; DEN, diethylnitrosamine; 2-AAF, 2-acetylaminofluorine.
become a malignant neoplastic cell. Prior to the onset of hepatic neoplasia, putative preneoplastic focal lesions have been observed (1,2). These morphologically distinct focal lesions exhibit altered gene expression and function when compared to normal, surrounding liver and appear to be precursors to malignant hepatocellular carcinoma, albeit, only a minority of these focal lesions will develop into hepatic cancer (1,2). Therefore, investigations into the growth of early preneoplastic lesions may aid in understanding those functions, genetic and epigenetic, that influence their progressive development into more autonomous lesions.
Chronic exposure to selected nongenotoxic chemicals results in the onset of hepatocellular cancer (3) (4) (5) (6) (7) (8) (9) . These agents do not interact with DNA directly and their mechanism of hepatocarcinogenic action is considered to be epigenetic (10). Studies by several groups have shown that continuous exposure to nongenotoxic hepatocarcinogens after treatment with an initiating carcinogen results in the increased growth of hepatic focal lesions (3, 11, 12, (19) (20) (21) (22) (23) (24) (25) suggesting that these compounds induce hepatic cancer by functioning at the stage of tumor promotion (3) (4) (5) .
A number of species-specific nongenotoxic hepatocarcinogenic organochlorine pesticides (aldrin, dieldrin, heptachlor, and endosulfan) have been proposed to be hepatic tumor promoters (10-12). Chronic exposure to dieldrin results in hepatic cancer in mice but not rats, hamsters, dogs, or monkeys (13-17). Similarly, recent studies have shown that dieldrin promoted the growth of preformed hepatic focal lesions in mice but not rats (18). In contrast, the barbiturate phenobarbital (PB*), a nongenotoxic hepatocarcinogen in both mice and rats, has been shown to promote the growth of preneoplastic focal lesions in both mice and rats (19) (20) (21) (22) (23) (24) (25) . These observations indicate that these nongenotoxic agents influence the growth of hepatic focal lesions by mechanisms that are species-specific.
In a variety of rat hepatocarcinogenesis models, it has been demonstrated that early preneoplastic lesions are reversible and disappear upon removal of the promoting stimulus (26) (27) (28) (29) . Chronic feeding of 5 mg diethylnitrosamine (DEN)/kg body weight per day to rats was cytotoxic and resulted in the formation of focal lesions that disappeared after cessation of treatment (26) . Three cycles of 2-acetylaminofluorine (2-AAF; 3 weeks feeding of 0.06% 2-AAF then 1 week on basal diet) resulted in the formation of macroscopic nodules that disappear a few months after the last cycle of treatment (27) . DEN treatment of partial hepatectomized rats followed by continuous treatment by PB resulted in the formation of altered hepatic foci that disappeared upon PB removal (28) . Also, DEN (200 mg/kg body weight) followed by partial hepatectomy and promoted with 2-AAF resulted in the formation of visible hyperplastic hepatic nodules (29) . Subsequent removal of 2-AAF resulted in a decrease in the number and size of hyperplastic nodules. These studies suggest that some altered hepatic foci in rats may require the continuous presence of a promoting agent to prevent their regression. A fundamental question regarding nongenotoxic inducedhepatocarcinogenesis is the stability and persistence of hepatic focal lesion growth following the removal of promoting stimuli. The studies mentioned above suggest some rat hepatic focal lesions require the presence of a promoting agent. Much less is known about the growth characteristics of mouse hepaticlesions. Lipsky reported that cessation of safrole treatment to mice after 52 weeks of exposure resulted in a decreased number of altered hepatic foci in mice (30). In addition, cessation of hexachlorocyclohexane treatment resulted in the loss of hyperplastic areas and focal lesions (31) . Reubner has suggested that the increased incidence of hepatocarcinogenicity in mice compared to rats may be attributed to an inability of early preneoplastic focal lesions to regress (32) . Numerous biological differences between early focal lesions in mice and rats have been reported and suggest that hepatic lesions in mice may respond differently to nongenotoxic treatment and cessation (33) (34) (35) .
Phenotypic diversity of focal preneoplastic lesions has been observed in mice and rats following treatment with different nongenotoxic hepatocarcinogens (36) (37) (38) . PB treatment has been shown to enhance the growth of focal lesions that are eosinophilic (25.37.38) and PB inhibits apoptosis. programmed cell death, preferentially in the eosinophilic lesions (25) . Previously, we have shown that dieldnn nonselectively promotes the growth of basophilic and eosinophilic hepatic focal lesions (18). Furthermore, dieldrin did not appear to inhibit apoptosis in either basophilic or eosinophilic lesions (18). These studies indicate that nongenotoxic hepatocarcinogens like dieldrin and PB preferentially enhance the growth of focal hepatic lesions by different mechanisms.
The present study investigated the differential effects of dietary PB and dieldrin in DEN-induced mouse hepatic focal lesion growth and the effect of removal of dieldrin and PB on focal preneoplastic liver lesions in DEN-initiated B6C3F1 mice. Specifically, we examined the changes in number and volume of hepatic focal lesions after treatment and removal of two known promoting agents (PB and dieldrin). Furthermore, the modulation of local lesion growth after dieldrin and PB treatment and removal was examined by investigating the incidence of apoptosis and DNA synthesis in distinct focal lesions after the removal of the promoting agent Materials and methods ( hi'Hiu ah DLN and PB I 1 )'*', puic) were purchased Ironi Sigma Chcinic.il Co Si Louis. MO Dieldnn |WJ pure) was pioudcd h\ Demugen. Inc . Smithwllc T\ NIH-07 diets containing 10 0 nig dieldnn/kg diet and 500 ing I'B/kg diet were lornnilated b\ Dyels Bethlehem PA CoiKentialions ol test compounds were \enlied as described previously (l')i
Animals antl t'xpt'imii'Mal tli'M^n
Three week-old male B6C3KI mice were puichascd liom ilarlan Spiagucl)awle\ Co (Indianapolis. IN) Mice were housed in |xil\caibonalc cages in an AAALAC accredited animal laciht\ All mice were maintained in accoidance with the NIH-Guide loi the Care and t'se ot Laboialoiy Animals All mice reeei\ed NIH-07 diet in pelleli/ed torm and deiom/cd water ail hhiuitn during a 1 week acclimation period At the conclusion ol the acclimation poiiod. B6C3H mice weie given two 35 mg DLN/kg NK1\ weight ip m|cctions per week Tor S weeks When local lesions were apparent (atlei 1 months), the mice were randomly placed into one ol the lollowing treatment groups (ti\c mice per group) Group A 10 days on NIH-07 diet (Control). Cnoup B 30 da\s on 10 0 mg dieldnn/kg NIII-07 diet. Croup C 10 days on 500 mg PB/kg NIH-07 did." Group D W) da\s on NIH-07 diet (Control). Group H. Ml days on 100 mg dicldrm/kg NIH-07 diet Group 1 Ml d.ns on 5(M) mg PB/kg NIH-07 diet. Group G 30 da\s on 100 mg dieldiin/kg NIH-07 diet then 30 days of NIH-07 diet Group II 30 days on 500 mg PB/kg NIH-07 diet 30 days ol NIH-07 diet Osmotic mini-pumps I model 2001 Al/et Co . Palo Alto. CA) containing hroiiHHlcoxvui uhne I BrdC). 1 fi ing/ml ot PBS ) were surgically implanted into live mice trom each tie.ilmenl group 7 clays prior to each sacnlice date At sampling, animals weie humanely killed by ether asphyxiation, weighed and necropsied The h\ers were iemo\cd in low. weighed and examined tor the presence ot grossly wsible lesions The Iners were then separated by lobe and sectioned into 1 2 mm strips Snips ol liver Irom each lobe were tixcd m lornialin lor 4S-72 h aiul then embedded in parattin A total ot three paralfm blocks pei animal were pioduecd Serial sections from each block w ere stained w ith hematoxvlin and eosin or submitted to iinmunohistochcmieal detection ot Brdl 1 (see below ) Hepatic prcneoplastic lesions were classified as previously described (40) Bnclly. mdmdual local lesions were classified as lollows Hepatocytcs in eosinophilic local lesions can be eithei smallei or largei than normal surrounding hepatocvles. howc\ei. in this study, they were larger than neighboring hepatcxytcs The cytoplasm has a distmt gianular appearance compared to ad|acent hepatocyles (40) HepakK'ytes in baMiphilic local lesions cm be' eithei smaller oi l.uuer than nonnal hepatoeytes. m this study. howe\er. they were smaller than normal hepatocytes The cytoplasm ot hcpaUKvtes in basophilic ItKal lesions is disiinclnely basophilic compared to adiacent hepatocytcs Clear local lesions (as well as \aculated local lesions) consist ot a clear, ground glass cytoplasm The cells m these focal lesions tend to be larger than nonnal hepatocytcs Both adenomas and carcinomas exist as distinct nodules which compress ad|acenl paienchyma and can bulge trom the h\er suhace Adenomas are composed ot cells that are well dillerenlialed. lorming a solid nodule that resembles normal liver No invasion ol ad|acent parenchymc but compression of the surrounding hepalocytes is ohsened on at least three sides of the lesion (41 i BrdU iinmiinohistocheinistry was perlonncd accoidmg to previously published methods with minor modihcations (42) llepalocvtcs that had incorporated Brdl 1 were easily visualized by the accumulation ol led pigment within the nuclei as compared to the counlerst.uned blue nuclei ol nonlabeled cells A stretch of duodenum Irom each animal was included on all slides to ensure profier staining and incorporation ot Brdt 1 into the tissues In local lesions, all hepatocytes were scored Labeling index (the jx'rcenlage ot cells in S-pha.sel was determined by dividing the nuinbei of hepalocytes with Bidl' labeled nuclei by the total number ol hepatocytcs counled
Slcnvlt>n\
The volume and number ol altered hepatic toci and neoplastic lesions were quantilated by stereologic methods (43) Bnelly. lotal liver aieas and hepalocellular lesions weie traced using a pro|cclion scope oi a drawing tube on a microscope respectively The h\er and lesion areas were calculated using Sigma Scan/Image software ( landel Scientific Corte Madre CA) on an IBM computer
AjHijItOSIS
Microscopic examination ol hematoxvlin and eosin stained slides was used to t|uanlitate the incidence ol apoplosis Apoptosis m the liver was defined and i|uantilated as previously desenbed (44.45) In addition, this manner ol identification ol apoptotic cells was further \ahdaled by using two dilterent Reversibility of tumor promotion methodologies: the Apoptag staining kit (Oncor Inc., Gaithersburg, MD) and a fluorescence microscopy method (46) . The number of apoptotic hepatocytes (at any morphological phase) in focal lesions was divided by the total number of hepatocytes in that lesion and multiplied by 100 to achieve an apoptotic index. Statistics
Statistical difference (P < 0.05) from control values for all data was determined by using ANOVA followed by a Dunnett's post hoc (47) .
Results
The effect of dieldrin treatment and cessation of treatment on body weight and relative liver weight (liver to body weight ratio) is shown in Table I . Treatment with dieldrin (30 days; Group E) resulted in an increased relative liver weight. Removal of dieldrin from the diet (Group G) was accompanied by return of the relative liver weight to that of mice on the control diet (Group D). The effect of PB treatment and cessation of treatment on body weight and relative liver weight (liver to body weight ratio) is also shown in Table I . PB treatment for 30 or 60 days (Groups C and F, respectively) resulted in increased relative liver weights compared to control (Groups A and D, respectively). Removal of PB from the diet (Group H) decreased the relative liver weight, when compared to continuously fed mice (Group F). No treatment significantly affected body weight at any time point examined (Table I ).
The number of focal lesions per liver in dieldrin-treated mice is shown in Table II . Exposure to dieldrin for 30 or 60 days (Groups B and E, respectively) increased the total number of focal lesions per liver. Eosinophilic lesions were preferentially effected as reflected by their increased number. Cessation of dieldrin treatment (Group G) significantly decreased the total number of focal lesions per liver. This decreased total number of focal lesions per liver was due to a decrease in the number of eosinophilic lesions. Table II also shows the number of focal lesions per liver in PB-treated mice. After 30 and 60 days of dietary exposure to PB (Groups C and F, respectively), an increase in the total number of focal lesions per liver was seen. Similar to dieldrin treated mice, the number of eosinophilic lesions was preferentially increased. Cessation of PB treatment (Group H) significantly decreased the total number of focal lesions per liver. In a similar manner to dieldrin-treated mice, this decreased total number of focal lesions per liver in PB-treated mice was due to a decrease in the number of eosinophilic lesions. The number of basophilic or clear focal lesions was not affected by any treatment at any time point examined (Table II) . Table HI shows the effect of dieldrin treatment and withdrawal on the focal lesion volume, expressed as percentage of total liver volume. Treatment with dieldrin for 30 and 60 days (Groups B and E, respectively) was accompanied by an increase in focal lesion volume. After 30 days of dieldrin treatment (Group B), the volume occupied by eosinophilic focal lesions was increased. After 60 days of dieldrin treatment (Group E), the hepatic focal volume of both basophilic and eosinophihc lesions was increased. Cessation of dietary treatment of dieldrin (Group G) was accompanied by a reduction in the volume of hepatic focal lesions (compare Groups G and E). Removal of dieldrin (Group G) from the diet decreased the volume occupied by eosinophilic lesions, but had no significant effect on any other lesion type examined. In fact, the volume of basophilic lesions in mice in Group G (dieldrin discontinued after 30 days) was not significantly different from that of mice fed dieldrin for 30 or 60 days (Groups B and E). The effect of PB treatment and cessation on (he focal lesion volume is also shown in Table III . PB treatment (30 days: Group C) increased the focal lesion volume. Despite the increased total focal volume, no significant increases in the hepatic focal volumes of any specific classes of foci were detected. However, after 60 days. PB treatment (Group F) significantly increased the volume in both basophilic and eosinophilic lesions. Cessation of dietary treatment of PB (Group H) decreased the volume of total focal lesions, compared to mice continuously fed PB (Group F). However the decrease could not be attributed to a specific class of lesions ( Table III) . The effect of dieldnn treatment and cessation on the DNA labeling index of focal lesions is shown in Table IV . After 30 and 60 days of dieldrin treatment (Groups B and E. respectively), an increase in the focal DNA labeling index was observed. After 30 or 60 days of treatment, dieldnn treatment significantly increased the labeling index of basophilic and eosinophilic lesions. Cessation of dietary treatment of dieldrin (Group G) had no observed effect upon the labeling index of all focal lesions, perhaps due to high interanimal variability However, removal of dieldrin from the diet significantly decreased the labeling index of basophilic and eosinophilic lesions. Table IV also shows the effect of PB treatment and cessation on the focal lesion DNA labeling index. PB treatment for 30 days (Group C) increased the total focal DNA labeling index After 30 days of treatment. PB treatment specifically increased the labeling index of basophilic lesions. However, after 60 days of treatment (Group F). PB significantly increased the labeling index of both eosinophilic and basophilic foci. Removal of PB from the diet (Group H) had no observed effect upon the labeling index of all focal lesions, perhaps due to high interanimal variability. However, removal of PB did decrease the labeling index of basophilic foci (Table IV) .
For comparison, the effect of promoter treatment and cessation on the DNA labeling index in normal surrounding liver is shown in Table V . Dieldrin treatment (Groups B and E) increased the labeling index of normal liver. Subsequent removal of dieldrin from the diet (Group G) decreased the labeling index of normal liver. In contrast, no increase in phenobarbital treated mice was observed at either time point.
The effect of dieldnn treatment and cessation on the incidence of apoptosis in focal lesions is shown in Table VI . Dieldrin treatment (Groups B and E) had no effect on the incidence of apoptosis in focal lesions. Regardless of the lack of dieldrin-induccd inhibition of apoptosis in foci, cessation of dieldnn (Group G) increased the incidence of apoptosis in foci (Figure 1 ). This increase in apoptosis in mice fonnerly fed dieldnn occurred in both eosinophilic and basophilic hepatic foci. Table VI also shows the effect of PB treatment and cessation on the incidence of apoptosis in focal lesions. In contrast, to the data mentioned above for dieldnn-treated foci, treatment with PB (30 and 60 days. Groups C and F) significantly decreased the incidence of apoptosis in hepatic foci and this decrease occurred in both basophilie and eosinophilic foci. Similar to dieldrin-treated mice, cessation of PB (Group H) drastically increased the incidence of apoptosis in focal lesions. The increased incidence of apoptosis observed after cessation of PB treatment occurred in both eosinophilic and basophilic hepatic foci (Table VI) .
The incidence of apoptosis in normal, surrounding liver is shown in Table VII . PB treatment (Groups C and F) decreased the incidence of apoptotic hepatocytes. In contrast, dieldrin treatment (Groups C and E) had no measurable effect on the incidence of apoptosis in normal surrounding non-focal hepatocytes. However, subsequent removal of either dieldrin (Group G) or PB (Group H) increased the incidence of apoptosis in non-focal hepatocytes
Discussion
This study demonstrated that feeding of dieldnn or PB to B6C3F1 mice stimulates the growth of DEN-induced hepatic foci. Eosinophilic lesions in particular showed an increase in lesion number and volume in mice fed either dieldrin or PB. Cessation of either dieldrin or PB exposure was accompanied by a decrease in the number and the volume of altered hepatic foci when compared to that seen in mice continuously fed the promoter. The regression of focal lesions following removal of either dieldrin or PB was primarily attributed to the loss of eosinophilic foci. This decrease in focal hepatocytes was directly related to an increased incidence of apoptosis, however, reversion of altered hepatocytes to a phenotype not demonstrable by hematoxylin and eosin staining cannot be precluded. This study indicates that dieldrin and PB promote hepatic focal lesions and that these lesions (eosinophilic in particular) are dependent on continuous exposure to the promoting agent.
Apoptosis has been clearly indicated as a mechanism for elimination of preneoplastic and normal hepatocytes following removal of growth stimulus (44, (48) (49) (50) (51) (52) . Schulte-Hermann and co-workers have shown that /V-nitrosomorpholine-initiated focal lesions promoted with PB had drastically elevated incidences of apoptosis after removal of PB treatment (45) . An alternative mechanism to explain the loss of focal lesions after promoter withdrawal proposes that focal hepatocytes 'revert' to a phenotype histologically indiscernible from surrounding normal hepatocytes (53) . It has been suggested that the actual number of focal lesions do not decrease after promoter cessation, but the rapid loss of volume can be attributed to the loss of detectable phenotype (28) . However, the rapid loss of foci volume, cither through apoptosts or reversion, would result in a decreased average volume of individual lesions and result in the observed decrease number of focal lesions (54) In the present study, the increased apoptosis in focal lesions occurring after removal of either dieldrin or PB was found to correlate with a decrease in the volume and number of focal lesions The relevance of the stability/instability of hepatic lesions to the carcinogenic process is unclear. It has been suggested that the focal lesions that persist after cessation of promoter treatment are the preneoplastic lesions that have the greatest potential to develop into tumors (27-29.31) . Hepatocytes in persistent lesions may have multiple genetic mutations and may already be in a stage of progression. Conversely, there are numerous endogenous promoting stimuli that have been identified that could enhance the growth of preneoplastic lesions such as sex steroids, bile acids, and pituitary hormones (55) (56) (57) (58) (59) . In addition, nutritional status e.g. dietary fat intake, tryptophan. methionine or choline deficiency, or sucrose intake may contribute to pathological changes and tumor promotion (55) (56) (57) (58) (59) (60) . Also, tmmunological status of the host, spectessusceptibihty and aging have been shown to contribute to the carcinogenic process (61) (62) (63) (64) . Since tumor promoting compounds enhance the number and incidence of focal lesions and cessation of promoter treatment results in a decrease in the number of lesions back to control values, the increased incidence of preneoplastic and neoplastic hepatic lesions induced by tumor promoters may occur by persistently enhancing the growth of local lesions. The chronic presence of a promoting agent enhances the proliferation and. possibly, inhibits apoptosis. thus increasing the probability of a mutational event required for the step-wise progression to malignancy (65) (66) .
These studies indicated that preneoplastic lesions promoted by nongenotoxic hepatocarcinogens in mice respond in a similar fashion to rats after removal of promoting stimulus. A variety of studies have shown that some rat hepatic lesions are dependent upon the continuous presence of a promoting agent. This study demonstrates that in mice the growth of some preneoplastic hepatic foci remains promoter-dependent after 30 days of continuous exposure to the promoter. In addition, two hepatic tumor promoting agents studied in this investigation, dieldrin and PB. appear to function by different mechanisms in enhancing focal lesion growth Further research is required to elucidate the mechanisms behind these differences. 
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